ArticleJAMA oncology2019

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.

Steven D Criss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.